PRR nomenclature:
The term "PRR" appears in multiple contexts across the search results, primarily referring to Pseudoresponse Regulator proteins (e.g., PRR5 in Arabidopsis circadian clock regulation ) or Pattern Recognition Receptors in immunology.
The number "95" does not align with established naming conventions for antibodies (e.g., anti-PD-1, anti-HER2) or PRR-related proteins.
| Source | Relevant Findings | PRR95 Antibody Mentioned? |
|---|---|---|
| Antibody structure/function | ❌ | |
| Malaria/RH5 or late-stage antibodies | ❌ | |
| PRR5 in plant biology | ❌ | |
| Clinical antibody studies | ❌ |
Potential typographical errors:
Unpublished research: The compound may be in early preclinical development without public data.
Verify the compound name with the original source (e.g., confirm "PRR95" vs. "PRR5" or "CD95").
Consult proprietary databases (e.g., Cortellis Drug Discovery Intelligence, CAS SciFinder) for confidential pipeline compounds.
Monitor updates to clinical trial registries (ClinicalTrials.gov, EU Clinical Trials Register).
PRR proteins (Pseudo-Response Regulators) are transcriptional regulators that play crucial roles in circadian clock systems. According to research, PRR9, PRR7, and PRR5 function as transcriptional repressors that directly downregulate CCA1 and LHY expression, which are core components of the circadian clock mechanism . These proteins associate with the CCA1 and LHY promoter regions, constituting an essential feedback loop of the circadian clock system . Their repressor activities are mediated through specific conserved motifs and require recruitment to DNA for functional activity.
PRR9, PRR7, and PRR5 contain conserved amino acid motifs that are critical for their repression activity. Research identifies specific motifs like (S/T)(D/E)(L/I)S(L/I)(R/K)R and SXXSAF(S/T)(R/Q)(Y/F) in these proteins that are essential for their function as transcriptional repressors . The proteins have been studied using fusion constructs with fluorescent proteins like CFP (Cyan Fluorescent Protein) to track their localization and activity in plant cells.
Researchers typically employ transient reporter assays to study PRR protein function. These assays include:
Luciferase reporter systems (e.g., CCA1pro:LUC, LHYpro:LUC, TOC1pro:LUC)
Fusion proteins with fluorescent tags (e.g., 35Spro:PRR9-CFP)
Glucocorticoid-inducible systems (e.g., 35Spro:5GC) for controlled expression
ChIP (Chromatin Immunoprecipitation) analyses to detect protein-DNA interactions
These systems allow researchers to quantify the effects of PRR proteins on target gene expression and identify their binding sites on DNA.
When developing antibodies against PRR proteins, researchers should consider:
Epitope selection: Target unique regions of each PRR protein to avoid cross-reactivity, especially given the sequence similarities among PRR family members
Validation approach: Use both wild-type and knockout/mutant samples (e.g., prr5-11 as mentioned in the literature) to confirm antibody specificity
Application compatibility: Ensure antibodies work in multiple applications (Western blotting, ChIP, immunoprecipitation)
Protein expression conditions: PRR proteins show circadian expression patterns, so timing of sample collection can affect antibody validation results
Specificity evaluation can be performed through multiple complementary approaches:
ChIP analyses comparing wild-type samples and knockout mutants (e.g., prr5-11) as negative controls
Western blotting against samples from overexpression lines (e.g., 35S:PRR5) and wild-type controls
Immunoprecipitation followed by mass spectrometry to identify potential cross-reactive proteins
Testing for cross-reactivity against related PRR family members
ChIP experiments for studying PRR protein-DNA interactions can be optimized by:
Careful selection of amplicons: Studies show significant enrichment of specific amplicons (e.g., amplicons 2, 3, 6, and 7) in the promoter regions of CCA1 and LHY when using tagged PRR proteins
Appropriate controls: Use non-tagged versions (e.g., 9pro:FGG, 7pro:FGG, 5pro:FGG) as negative controls
Timing considerations: Since PRR proteins are involved in circadian regulation, collection timing can significantly affect results
Antibody validation: Ensure that antibodies used for ChIP are highly specific, as demonstrated in the literature using anti-PRR5 antibody against both prr5-11 and 35S:PRR5 samples
To distinguish the functions of PRR family members:
Use reporter assays with different promoters: Research shows PRR9, PRR7, and PRR5 all downregulate CCA1 and LHY but have different effects on TOC1 expression
Employ protein domain swapping experiments to identify functional domains
Create fusion proteins with heterologous DNA binding domains (e.g., GAL4DB-PRR fusions) to isolate repression activity from DNA binding specificity
Use translational inhibitors like cycloheximide (CHX) to distinguish direct from indirect effects
Recent advances in antibody design leverage machine learning models like DyAb that can predict protein properties from limited training data. Key strategies include:
Sequence-based prediction: Using protein sequence data to predict antibody properties
Genetic algorithm (GA) approaches: Using algorithms that systematically test combinations of mutations to optimize binding affinity
Edit distance considerations: Limiting designs to low edit distances (ED ≤ 7) from starting sequences to maintain "natural" antibody characteristics
Embedding models: Utilizing protein language models like AntiBERTy or LBSTER for sequence representation
For optimizing antibody binding affinity, researchers can follow this methodological approach:
Start with alanine scanning or point mutation analysis to identify beneficial individual mutations
Combine promising mutations (typically 3-4 at a time) to generate new candidate sequences
Use predictive models like DyAb to score combinations and estimate affinity differences (ΔpKD)
Express and validate top candidates experimentally using surface plasmon resonance (SPR)
This approach has demonstrated high success rates, with studies showing >85% of designed antibodies successfully expressing and binding to target antigens .
When facing contradictory results between antibody-based and PCR-based methods:
Consider the different biological implications: Antibody responses provide evidence of past infection or protein expression, while PCR tests detect current presence of nucleic acids
Examine detection limits: In population studies of SARS-CoV-2, seropositivity rates were considerably higher than cumulative PCR-based prevalence, suggesting antibody testing provides a more complete picture of past infection
Account for timing: In one study, 28% of participants with antibodies against SARS-CoV-2 never underwent PCR testing, and at least one-third of seropositive participants had no history of symptoms
Validate results with multiple methods: When possible, use complementary approaches to confirm findings
When analyzing antibody binding data, researchers should consider:
Prevalence Rate Ratios (PRR) with 95% confidence intervals to compare seropositivity rates across different populations or time periods
Appropriate statistical tests (e.g., t-tests) to determine significant differences in antibody responses
Stratification by relevant variables: Data can be meaningfully analyzed when stratified by factors such as:
For research-grade antibody production:
Mammalian expression systems: Expi293 cells are commonly used for transient expression of antibodies with high success rates (>85% for designed antibody variants)
Cloning approach: Gibson assembly into mammalian expression vectors following gene synthesis is an effective workflow
Scale considerations: Small-scale cultures (1 mL) can be sufficient for initial validation
Purification method: Standard protein A-based purification methods are effective for most research applications
Surface plasmon resonance (SPR) is considered one of the most reliable methods for measuring antibody binding affinity:
Temperature control: Measurements at physiologically relevant temperatures (37°C) provide the most meaningful data
Buffer composition: HBS-EP+ buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 0.3mM EDTA, 0.05% Surfactant P20) is commonly used
Measurement approaches:
Capture method: Protein A capture followed by antigen injection allows for controlled orientation of antibodies